InvestSMART

Imricor Medical Systems Inc (ASX:IMR)

ALERT: Price-sensitive ASX Announcement for IMR
Current share price for IMR : $1.930 -0.045 (-2.28%)+
Announcement
Release
4 May 2026 9:12AM
Price at Release
$1.975
Full Release
download
Summary
Imricor Medical Systems, Inc. announced a successful capital raise of A$60 million through a placement to institutional and sophisticated investors, priced at A$1.85 per CDI, which represents a discount to the last traded price. The funds raised will bolster Imricor's strategic initiatives, including the launch of NorthStar in the U.S. and further regulatory advancements. The company expects substantial cash reserves post-placement, enabling progress on commercial and regulatory fronts. The institutional placement was managed by Morgans Corporate Limited, Canaccord Genuity (Australia) Limited, and Taylor Collison Limited. The initiative marks a significant step in scaling Imricor's operations.
Key Points
  • Imricor Medical Systems, Inc. successfully raised A$60 million through a placement with new and existing institutional and sophisticated investors.
  • The funds will support the launch of NorthStar in the U.S., advance regulatory approvals for the Electrophysiology platform, and complete key clinical programs.
  • Approximately A$102.9 million in cash reserves is expected post-placement.
  • Placement was completed at an offer price of A$1.85 per CDI, representing a 6.3% discount to the last traded price.
  • The completion of the placement positions Imricor to execute on its commercial, clinical, and regulatory objectives.
  • Morgans Corporate Limited, Canaccord Genuity (Australia) Limited, and Taylor Collison Limited acted as Joint Lead Managers.
  • Steve Wedan, Imricor’s Chair and CEO, emphasized the capital raise will help move from momentum to scale.
  • The indicative timetable included trading resumption on 4 May 2026 and settlement of New CDIs on 7 May 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.